Phaseline

Companies › Calixis

Calixis: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
THB335–Phase 2Chronic Spontaneous Urticaria (CSU)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07766499THB335Phase 2Chronic Spontaneous Urticaria (CSU)ImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing) Agomab Spain S.L.U.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.